US EditionIndian Billionaire Dilip Shanghvi’s Sun Pharma To Buy U.S. Cancer Drug Maker For $355 Million
- Sun Pharmaceutical Industries Inc. Has agreed to acquire Checkpoint Therapeutics for an upfront cash payment of $4.10 per share, totaling up to $355 million.
- The acquisition includes a contingent value right for Checkpoint stockholders, potentially adding $0.70 per share based on FDA approval milestones.
- The transaction aims to accelerate access to UNLOXCYT, the first FDA-approved anti-PD-L1 treatment for advanced cutaneous squamous cell carcinoma.
- Completion of the acquisition is pending approval from Checkpoint's stockholders and other customary closing conditions.
Insights by Ground AI
Does this summary seem wrong?
62 Articles
62 Articles
All
Left
3
Center
22
Right
3
Top India Drugmaker Sun to Buy US Oncology Firm for $355 Million
Sun Pharmaceutical Industries Ltd. has agreed to buy US-based immunotherapy and oncology firm Checkpoint Therapeutics Inc. for an upfront payment of $355 million, as India’s largest drugmaker bolsters its specialty therapy portfolio.
·United States
Read Full Article
Buffalo News+45 Reposted by 45 other sources
Sun Pharma to Acquire Checkpoint Therapeutics
Will add UNLOXCYT™ (cosibelimab-ipdl), the first and only FDA-approved anti-PD-L1 treatment for
·Buffalo, United States
Read Full Article
Indian Billionaire Dilip Shanghvi’s Sun Pharma To Buy U.S. Cancer Drug Maker For $355 Million
Sun Pharmaceutical Industries—controlled by Indian billionaire Dilip Shanghvi—has agreed to buy U.S.-based immunotherapy and oncology company Checkpoint Therapeutics for $355 million to bolster the Mumbai-based company’s drug portfolio.
·United States
Read Full ArticleCoverage Details
Total News Sources62
Leaning Left3Leaning Right3Center22Last UpdatedBias Distribution79% Center
Bias Distribution
- 79% of the sources are Center
79% Center
11%
C 79%
11%
Factuality
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
